Inch­ing clos­er to block­buster sta­tus, Seat­tle Ge­net­ics gets fourth FDA win for Ad­cetris

Seat­tle Ge­net­ics $SGEN has bagged an­oth­er ap­proval for its flag­ship ther­a­py Ad­cetris — now the fourth in­di­ca­tion for the can­cer drug.

The FDA ap­proved Ad­cetris …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER